Trial Profile
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PEONY
- Sponsors Roche
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2017 Planned End Date changed from 1 Sep 2023 to 30 Apr 2022.